Issue 2/2022
Content (20 Articles)
New targeted therapies/small molecules in oncology and hematology
Anna Sophie Berghoff
COVID-19: New disease mechanism is simultaneously a therapeutic target
Clemens A. Schmitt
Renal cell carcinoma—presentation highlights from the ESMO Congress 2021
Georg C. Hutterer, Martin Pichler
Breast Cancer—Essential news of current guidelines
Kathrin Strasser-Weippl
Agony of choice—selecting chronic lymphocytic leukemia treatment in 2022
Jan-Paul Bohn
Current state of clinical development of TROP2-directed antibody–drug conjugates for triple-negative breast cancer
Maximilian Marhold
New targeted therapies in kidney cancer
Karl Mayrhofer, Dora Niedersüß-Beke
Tracking mutation and drug-driven alterations of oncokinase conformations
Andreas Feichtner, Valentina Kugler, Selina Schwaighofer, Thomas Nuener, Jakob Fleischmann, Eduard Stefan
Systemic capillary leak syndrome following granulocyte colony-stimulating factor therapy in a T-lymphoblastic leukemia/lymphoma patient: a case report
Ahmed H. Al Sharie, Yazan O. Al Zu’bi, Sarah Al Sharie, Hawra A. Baydoun, Farah H. Atawneh, Osama Alshari, Dima Albals
Hemophagocytic lymphohistocytosis in a COVID-19 patient in the acute phase: case report
Maher Salamoon, Mazen Kenj
High mortality in patients with active malignancy and severe COVID-19
Simon Udovica, Nino Müser, Agnes Pechlaner, Andreas Reichinger, Christoph Aichinger, Kathrin Strasser-Weippl, Holger Rumpold, Andreas Petzer, Ewald Wöll, Wolfgang Hilbe, Ercan Müldür
Cardiopulmonary sequelae of COVID-19
Neurotoxicity as a rare side effect of immune checkpoint inhibitors. A case report and review of the literature
Simon Udovica, Kathrin Strasser-Weippl, Eva Fischer, Dora Niedersüß-Beke
Immunotherapy pitfall: sarcoid-like reaction mimicking disease progression in advanced melanoma treated with nivolumab
Beatrix Mutschlechner, Susanne Dertinger, Felix Offner, Veronika Buck, Alexander Becherer, Klaus Gasser, Bernd Hartmann, Thomas Winder